Extension Study Evaluating Etanercept in 3 Subtypes of Childhood Arthritis
Status:
Completed
Trial end date:
2021-02-04
Target enrollment:
Participant gender:
Summary
This is a 8-year extension study in pediatric subjects who have been diagnosed with one of 3
subtypes of Juvenile Idiopathic Arthritis (JIA) [extended oligoarticular JIA, enthestitis
related arthritis (ERA), or psoriatic arthritis (PsA)] who have completed approximately 96
weeks of participation in study 0881A1-3338 (B1801014). The study contains an active
treatment period, withdrawal/re-treatment period and a observational period (non-treatment).